H2S generated by three different enzymes including cystathionine-β-synthase (CBS) contributes to somatic and visceral pain by enhancing the activity of Cav3.2, an isoform of T-type Ca2+ channels (T-channels). Most recently, we have developed KTtp38, a novel derivative of the antipsychotic pimozide, that potently inhibits T-channels, but has little affinity to D2 receptors. Here, we investigated the effects of KTtp38 on Cav3.2-dependent pain, i.e. the somatic and/or colonic pain/hypersensitivity caused by Na2S, an H2S donor, or butyrate, and also on the colonic hypersensitivity caused by 2,4,6-trinitrobenzene sulfonic acid (TNBS) in mice. Oral administration of KTtp38 potently suppressed somatic and visceral pain following intraplantar and intracolonic (i.col.) administration of Na2S, respectively, and the colonic distention hypersensitivity following repeated i.col. butyrate. A single i.col. TNBS caused delayed colonic distention hypersensitivity accompanied by colonic CBS upregulation, which was inhibited by i.p. aminooxyacetic acid, a CBS inhibitor or deletion of Cav3.2 gene. Oral or i.p. KTtp38 suppressed the TNBS-induced colonic hypersensitivity. Thus, KTtp38 suppresses Cav3.2-dependent somatic and visceral pain, and is considered useful to treat pathological pain involving H2S and/or Cav3.2.